The efficacy, safety and tolerability of canakinumab in the treatment of familial Mediterranean fever : a systematic review of the literatureMark Kačar
, Sinisa Savic
, Jeroen CH van der Hilst
, 2020, pregledni znanstveni članek
Povzetek: Familial Mediterranean Fever (FMF) is the most prevalent genetic autoinflammatory disorder. In most patients, treatment with colchicine can prevent attacks of fever and inflammation. However, 5%-10% of patients are resistant to colchicine treatment, while a similar percentage cannot tolerate colchicine in doses needed to prevent attacks. For these patients, Canakinumab, a full human antibody against IL-1[beta], has been approved recently by the FDA and EMA. In this article, we present a systematic review of the long-term efficacy, safety, and tolerability of Canakinumab in FMF patients who cannot tolerate colchicine or who are resistant to colchicine treatment.
Ključne besede: familial Mediterranean fever -- therapy -- review, monoclonal antibodies, canakinumab, anti-IL1 therapy
Objavljeno v DiRROS: 08.04.2021; Ogledov: 779; Prenosov: 392
Celotno besedilo (463,72 KB)
Gradivo ima več datotek! Več...